NCT00439634View on ClinicalTrials.gov

Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

PHASE2TerminatedINTERVENTIONAL

Enrollment

873

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Schizophrenia

Interventions

DRUG

AVE1625

oral administration

DRUG

placebo

oral administration

Trial Locations (2)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Laval

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY